Biogen CSO Artavanis-Tsakonas heads back to Harvard, lab funding in hand
Almost exactly four years after being named permanent chief scientific officer at Biogen, Spyros Artavanis-Tsakonas has now quietly left the company, according to a report in the Boston Business Journal.
The cell biology specialist has been a professor at Harvard Medical School since 1999. And now he’s headed back with funding from Biogen on new research into neurodegenerative diseases. The big biotech gets an option on licensing new tech from his lab in exchange for the funding, according to the BBJ, which cited Biogen’s proxy statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.